Literature DB >> 24526448

Lrg participates in lipopolysaccharide preconditioning-induced brain ischemia injury via TLR4 signaling pathway.

Gu Gong1, Shurong Bai, Wei Wu, Ling Hu, Yinghai Liu, Jie Niu, Xuemei Dai, Liang Yin, Xiaowu Wang.   

Abstract

Lipopolysaccharide (LPS) preconditioning is a powerful neuroprotective phenomenon by which an injurious stimulus renders the brain resistant to a subsequent damaging ischemic insult. The LPS response gene (Lrg) is a recently identified gene in human dental pulp cells treated with LPS. However, the role and mechanism of Lrg in brain ischemia injury have not yet been demonstrated. Here, we sought to determine whether Lrg participates in LPS preconditioning-induced brain ischemia injury. The Lrg protein accumulates in brain tissue after middle cerebral artery occlusion (MCAO). Furthermore, knockdown of Lrg by small interfering RNA (siRNA) significantly increased the infarct size of brain injury. In addition, we investigated the mechanism of Lrg in brain ischemia injury. Lrg-siRNA could regulate inflammatory cytokine expression. Moreover, interleukin-1 receptor-associated kinase 1 (IRAK-1) and nuclear factor Kappa B (NF-κB) p65 protein levels were significantly increased by Lrg-siRNA in mice after MCAO. Conversely, interferon regulatory factor 3 (IRF3) protein level was decreased by Lrg-siRNA. Taken together, these results suggest that Lrg regulates the expression of inflammatory cytokines in LPS preconditioning-induced brain ischemia injury via the toll-like receptor 4 (TLR4) signaling pathway. Lrg may therefore serve as a novel therapeutic target for brain ischemia injury.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24526448     DOI: 10.1007/s12031-014-0240-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  28 in total

Review 1.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

2.  Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells.

Authors:  X-L Jiao; C Zhao; M Niu; D Chen
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-07       Impact factor: 3.507

3.  Conditioned blood reperfusion markedly enhances neurologic recovery after prolonged cerebral ischemia.

Authors:  Bradley S Allen; Manuel Castellá; Gerald D Buckberg; Zhongtou Tan
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

Review 4.  KATP channels and myocardial preconditioning: an update.

Authors:  Garrett J Gross; Jason N Peart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09       Impact factor: 4.733

Review 5.  Early events in the recognition of danger signals after tissue injury.

Authors:  David J Kaczorowski; Kevin P Mollen; Rebecca Edmonds; Timothy R Billiar
Journal:  J Leukoc Biol       Date:  2007-11-21       Impact factor: 4.962

6.  Endotoxin tolerance dysregulates MyD88- and Toll/IL-1R domain-containing adapter inducing IFN-beta-dependent pathways and increases expression of negative regulators of TLR signaling.

Authors:  Wenji Piao; Chang Song; Haiyan Chen; Marco A Quevedo Diaz; Larry M Wahl; Katherine A Fitzgerald; Liwu Li; Andrei E Medvedev
Journal:  J Leukoc Biol       Date:  2009-08-05       Impact factor: 4.962

Review 7.  Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart.

Authors:  Wei Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-14       Impact factor: 4.733

Review 8.  Toll-like receptors in cerebral ischemic inflammatory injury.

Authors:  Yan-Chun Wang; Sen Lin; Qing-Wu Yang
Journal:  J Neuroinflammation       Date:  2011-10-08       Impact factor: 8.322

Review 9.  Post-infarct remodelling: contribution of wound healing and inflammation.

Authors:  Stefan Frantz; Johann Bauersachs; Georg Ertl
Journal:  Cardiovasc Res       Date:  2008-10-31       Impact factor: 10.787

Review 10.  TLR2 and TLR4 in the brain injury caused by cerebral ischemia and reperfusion.

Authors:  Ying Wang; Pengfei Ge; Yuhong Zhu
Journal:  Mediators Inflamm       Date:  2013-06-23       Impact factor: 4.711

View more
  7 in total

1.  CD200Fc reduces TLR4-mediated inflammatory responses in LPS-induced rat primary microglial cells via inhibition of the NF-κB pathway.

Authors:  Li Jiang; Fan Xu; Wenjing He; Lifei Chen; Haibin Zhong; Yu Wu; Siming Zeng; Li Li; Min Li
Journal:  Inflamm Res       Date:  2016-03-08       Impact factor: 4.575

2.  Systems approach to the study of brain damage in the very preterm newborn.

Authors:  Alan Leviton; Pierre Gressens; Olaf Wolkenhauer; Olaf Dammann
Journal:  Front Syst Neurosci       Date:  2015-04-14

3.  'Preconditioning' with low dose lipopolysaccharide aggravates the organ injury / dysfunction caused by hemorrhagic shock in rats.

Authors:  Regina Sordi; Fausto Chiazza; Nimesh S A Patel; Rachel A Doyle; Massimo Collino; Christoph Thiemermann
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

Review 4.  Rational modulation of the innate immune system for neuroprotection in ischemic stroke.

Authors:  Diana Amantea; Giuseppe Micieli; Cristina Tassorelli; María I Cuartero; Iván Ballesteros; Michelangelo Certo; María A Moro; Ignacio Lizasoain; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2015-04-29       Impact factor: 4.677

Review 5.  Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia.

Authors:  Man Li; Jing Liu; Ying Bi; Jixiang Chen; Lei Zhao
Journal:  Curr Neuropharmacol       Date:  2018-01-30       Impact factor: 7.363

6.  Saikosaponin A attenuates neural injury caused by ischemia/reperfusion.

Authors:  Xinying Wang; Guofeng Yang
Journal:  Transl Neurosci       Date:  2020-07-02       Impact factor: 1.757

7.  Toll‑Like receptor 4 promotes the phosphorylation of CRMP2 via the activation of Rho‑kinase in MCAO rats.

Authors:  Xue-Bo Li; Ming-Xia Ding; Chun-Li Ding; Liang-Liang Li; Jinzhou Feng; Xiao-Jun Yu
Journal:  Mol Med Rep       Date:  2018-05-03       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.